LAPIX Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- LAPIX Therapeutics's estimated annual revenue is currently $1.1M per year.
- LAPIX Therapeutics's estimated revenue per employee is $100,500
Employee Data
- LAPIX Therapeutics has 11 Employees.
- LAPIX Therapeutics grew their employee count by 38% last year.
LAPIX Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
2 | Cofounder | Reveal Email/Phone |
3 | Head Immunology | Reveal Email/Phone |
4 | Director DMPK and Clinical Pharmacology | Reveal Email/Phone |
5 | CMC and Formulation Director | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
LAPIX Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is LAPIX Therapeutics?
LAPIX is an immune system modulation company with 2 distinct therapeutic pipelines; LAPIX-IO and LAPIX-TI.LAPIX-IO replaces multiple checkpoint inhibitors with a single standalone product delivered orally. LAPIX-TI is an alternative to the wrecking ball approach of immunosuppressants. LAPIX-TI has applications in the treatment of auto-immune disorders as well as tolerance induction for gene therapy and enzyme replacement therapy.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.1M
Revenue (est)
38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.8M | 11 | -31% | $19.6M |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $0.9M | 11 | N/A | N/A |
#5 | $0.9M | 11 | -8% | $11.2M |